Golden State Wealth Management LLC boosted its position in shares of Axon Enterprise, Inc. (NASDAQ:AXON – Get Rating) by 4.0% during the first quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 6,172 shares of the biotechnology company’s stock after purchasing an additional 240 shares during the quarter. Golden State Wealth Management LLC’s holdings in Axon Enterprise were worth $850,000 at the end of the most recent reporting period.
A number of other institutional investors also recently bought and sold shares of AXON. Capital International Investors boosted its position in Axon Enterprise by 605.2% during the first quarter. Capital International Investors now owns 2,660,634 shares of the biotechnology company’s stock worth $366,449,000 after purchasing an additional 2,283,343 shares in the last quarter. BlackRock Inc. boosted its position in Axon Enterprise by 6.2% during the fourth quarter. BlackRock Inc. now owns 7,366,629 shares of the biotechnology company’s stock worth $1,156,559,000 after purchasing an additional 426,830 shares in the last quarter. State Street Corp boosted its position in Axon Enterprise by 13.3% during the first quarter. State Street Corp now owns 2,220,692 shares of the biotechnology company’s stock worth $305,856,000 after purchasing an additional 261,508 shares in the last quarter. Capital Group International Inc. CA boosted its position in Axon Enterprise by 263.6% during the first quarter. Capital Group International Inc. CA now owns 286,404 shares of the biotechnology company’s stock worth $39,446,000 after purchasing an additional 207,638 shares in the last quarter. Finally, Renaissance Technologies LLC purchased a new stake in Axon Enterprise during the fourth quarter worth $31,440,000. 78.44% of the stock is currently owned by hedge funds and other institutional investors.
Analyst Ratings Changes
A number of equities analysts have recently weighed in on the company. Credit Suisse Group boosted their price target on Axon Enterprise from $134.00 to $142.00 and gave the stock an “outperform” rating in a report on Wednesday, August 10th. JMP Securities reissued a “buy” rating and issued a $195.00 price target on shares of Axon Enterprise in a report on Wednesday, June 1st. Morgan Stanley cut Axon Enterprise from an “overweight” rating to an “equal weight” rating and set a $120.00 price target for the company. in a report on Monday, May 23rd. Robert W. Baird boosted their price target on Axon Enterprise from $130.00 to $150.00 and gave the stock an “outperform” rating in a report on Thursday, August 18th. Finally, StockNews.com cut Axon Enterprise from a “buy” rating to a “hold” rating in a report on Wednesday, August 10th. Two analysts have rated the stock with a hold rating and seven have issued a buy rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $166.38.
Axon Enterprise Stock Performance
Axon Enterprise stock opened at $120.01 on Thursday. The firm has a market capitalization of $8.53 billion, a P/E ratio of 61.54 and a beta of 0.64. The stock has a fifty day moving average price of $118.83 and a 200 day moving average price of $103.52. Axon Enterprise, Inc. has a 52 week low of $82.49 and a 52 week high of $209.00. The company has a current ratio of 2.70, a quick ratio of 2.35 and a debt-to-equity ratio of 0.02.
Axon Enterprise (NASDAQ:AXON – Get Rating) last announced its quarterly earnings results on Tuesday, August 9th. The biotechnology company reported $0.71 EPS for the quarter, topping the consensus estimate of $0.09 by $0.62. The company had revenue of $285.61 million during the quarter, compared to analyst estimates of $258.96 million. Axon Enterprise had a return on equity of 12.57% and a net margin of 14.20%. The firm’s revenue was up 30.5% on a year-over-year basis. During the same period in the prior year, the firm posted ($0.72) earnings per share. Equities research analysts anticipate that Axon Enterprise, Inc. will post 0.39 earnings per share for the current year.
About Axon Enterprise
Axon Enterprise, Inc develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, TASER, and Software and Sensors. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence.
Receive News & Ratings for Axon Enterprise Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Axon Enterprise and related companies with MarketBeat.com’s FREE daily email newsletter.